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Abstract
Aims Ivabradine has been approved in heart failure with reduced ejection fraction (HFrEF) and elevated heart rate despite
guideline-directed medical therapy (GDMT) to reduce cardiovascular (CV) death and hospitalization for worsening HF. The me-
dian value of 77 b.p.m. is the lower bound selected for the regulatory approval in Canada, South Africa, and Australia. Patient-
reported outcomes (PROs) including symptoms, quality of life, and global assessment are considered of major interest in the
global plan of care of patients with HF. However, the speciﬁc impact of GDMT, and speciﬁcally ivabradine, on PRO remains
poorly studied. In the subgroup of patients from the Systolic Heart failure treatment with the If inhibitor ivabradine Trial
(SHIFT) who had heart rate above the median of 77 b.p.m. (pre-speciﬁed analysis) and for whom the potential for improve-
ment was expected to be larger, we aimed (i) to evaluate the effects of ivabradine on PRO (symptoms, quality of life, and
global assessment); (ii) to consolidate the effects of ivabradine on the primary composite endpoint of CV death and hospital-
ization for HF; and (iii) to reassess the effects of ivabradine on left ventricular (LV) remodelling.
Methods and results Comparisons were made according to therapy, and proportional hazards models (adjusted for baseline
beta-blocker therapy) were used to estimate the association between ivabradine and various outcomes. In SHIFT, n = 3357
(51.6%) patients had a baseline heart rate > 77 b.p.m. After a median follow-up of 22.9 months (inter-quartile range 18–28
months), ivabradine on top of GDMT improved symptoms (28% vs. 23% improvement in New York Heart Association func-
tional class, P = 0.0003), quality of life (5.3 vs. 2.2 improvement in Kansas City Cardiomyopathy Questionnaire overall summary
score, P = 0.005), and global assessment [from both patient (improved in 72.3%) and physician (improved in 61.0%) perspec-
tives] signiﬁcantly more than did placebo (both P < 0.0001). Ivabradine induced a 25% reduction in the combined endpoint of
CV death and hospitalization for HF (hazard ratio 0.75; P < 0.0001), which translates into a number of patients needed to be
treated for 1 year of 17. Patients under ivabradine treatment demonstrated a signiﬁcant reduction in LV dimensions when
reassessed at 8 months (P < 0.05).
Conclusions In patients with chronic HFrEF, sinus rhythm, and a heart rate > 77 b.p.m. while on GDMT, the present analysis
brings novel insights into the role of ivabradine in improving the management of HFrEF, particularly with regard to PRO
(ISRCTN70429960).
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Introduction
In the Systolic Heart failure treatment with the If inhibitor
ivabradine Trial (SHIFT), ivabradine, a speciﬁc If-channel in-
hibitor, resulting in a pure heart rate reduction, signiﬁcantly
reduced the composite endpoint of cardiovascular (CV)
death and heart failure (HF) hospitalization in patients with
chronic HF and reduced ejection fraction [left ventricular
ejection fraction (LVEF) ≤ 35%] who were in sinus rhythm
and had resting heart rate ≥ 70 b.p.m. despite optimal med-
ical therapy.1 Subgroup analyses demonstrated a constant
improvement in outcomes across the whole spectrum
of heart rate, with a signiﬁcant relationship between base-
line heart rate and treatment effect (higher being better).2
Various heart rates have been approved for this
indication by the international regulatory authorities,3–5 with
77 b.p.m. being the cut-off value in Canada, South Africa,
and Australia.
Patient-reported outcomes (PROs) such as symptoms,
quality of life, and global assessment gained interest in the
global plan of care of patients with HF, becoming key aspects
with regard to the management of patient’s experience with
chronic disease and being at least as important as survival
from patients’ perspective.6 As such, PRO measures provide
useful insights into the impacts of symptoms on patients
functioning and are currently encouraged as an outcome
measure in clinical trials as well as a marker of high-quality
care in clinical practice.7,8
Although the exact interplay between medical therapy
and improved PROs remains largely speculative, PROs
showed to be strong predictors of mortality and recurrent
admissions in HF.9 As such, baseline Kansas City Cardiomy-
opathy Questionnaire (KCCQ)10 was shown to be associated
with prognosis in patients with HF11,12; and even small
changes in quality of life related to various pharmacological
and non-pharmacological interventions have recently been
demonstrated to be associated with better outcomes,13–16
especially when co-occurring with improvements in cardiac
status.17,18 However, the speciﬁc impacts of guideline-
directed medical therapy (GDMT), and particularly iva-
bradine, on PRO (i.e. beyond simple assessment of quality
of life) remains poorly studied in HF with reduced ejection
fraction (HFrEF).
Therefore, we aimed to better characterize the potential
beneﬁt associated with ivabradine on PRO in the subgroup
of patients from the SHIFT trial with heart rates at rest of at
least the median value of 77 b.p.m., as the potential for im-
provement was expected to be larger in those patients given
its mode of action.19 As such, the present analysis aimed (i) to
evaluate the effects of ivabradine on PROs (symptoms, qual-
ity of life, and global assessment); (ii) to consolidate the ef-
fects of ivabradine on the primary composite endpoint of
CV death and hospitalization for HF; and (iii) to reassess the
effects of ivabradine on LV remodelling.
Methods
Study design
The overall objective of the SHIFT trial was to assess the role
of ivabradine on top of current GDMT in chronic HFrEF.1 The
design and primary results of the trial have extensively been
described elsewhere.1,20 Brieﬂy, patients with HF, reduced
left ventricular function (LVEF ≤ 35%), New York Heart Asso-
ciation (NYHA) functional class II–IV, and persistent heart rate
≥ 70 b.p.m. at rest (sinus rhythm) despite GDMT were eligible
for randomization in SHIFT, with a majority of patients being
already treated with the highest tolerated doses of beta-
blockers or having a contraindication or intolerance to them.
A total of 6505 patients were randomized to receive either
ivabradine or placebo. The primary outcome was a composite
of death from CV causes or hospitalization for worsening HF.
Secondary endpoints were CV hospitalization, CV death, hos-
pitalization for HF, HF death, all-cause hospitalization, and all-
cause death. Changes in functional capacity were assessed
using the NYHA functional class and by patient-reported
and physician-reported global assessment. Physician global
assessment was based on a scoring system assessing changes
in functional status (‘markedly improved’, ‘moderately im-
proved’, ‘slightly improved’, ‘no change’, ‘slightly worsened’,
‘moderately worsened’, or ‘markedly worsened’). Patient
self-assessment was based on a separate questionnaire eval-
uating changes in health status (‘markedly improved’, ‘mod-
erately improved’, ‘slightly improved’, ‘no change’, ‘slightly
worsened’, ‘moderately worsened’, or ‘markedly worsened’).
Patients were blinded to physician global assessments and
vice versa. Quality of life was assessed using the Food and
Drug Administration-approved KCCQ. All assessments were
provided under treatment at baseline, 4 months, 12 months,
24 months, or last follow-up.1,15
The SHIFT echocardiography sub-study included 411 pa-
tients (ivabradine, n = 208; and placebo, n = 203), and the pri-
mary endpoint was the change in left ventricular end-systolic
volume index (LVESVi; mL/m2) over time (measures were ob-
tained at baseline and 8 months). The ancillary study design
has also been published.15,21
Statistical considerations
We assessed outcomes in the patients with a heart rate ≥
77 b.p.m. (i.e. median heart rate at baseline in patients in-
cluded in the SHIFT trial), and comparisons were made regard-
ing study treatment. Baseline characteristics are summarized
using counts and percentages for categorical variables and
mean ± standard deviation or median [inter-quartile range
(IQR)] for continuous variables. The effects of ivabradine com-
pared with placebo on pre-speciﬁed outcomes are provided
using a Cox’s proportional hazards model including treatment
as a factor and adjusted for baseline beta-blocker therapy (yes
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or no). Hazard ratios (HRs) and 95% conﬁdence intervals (CIs)
were estimated, and P-values calculated from the Wald statis-
tic. Time-to-event curves by treatment group were estimated
using the Kaplan–Meier method. The number of patients
needed to be treated (NNT) for 1 year in order to prevent
one event was calculated as the inverse of the between-
treatment group difference of the estimated probability of
having an event at 1 year in the Kaplan–Meier curves. All sur-
vival analyses were based on endpoints adjudicated by an in-
dependent committee blinded to treatment allocation and
were conducted as time-to-ﬁrst event using the intention-to-
treat principle. The percentages of patients improving their
NYHA class and patient-reported and physician-reported
global assessment were compared using a χ2 test. Changes in
echocardiographic endpoints (at Week 8) and KCCQ scores
(at Week 12) were compared between treatment groups on
patients included in the corresponding substudies using a co-
variance analysis adjusted for beta-blocker intake at randomi-
zation, country, and baseline value. The treatment effect was
estimated using adjusted least square means from this model,
with associated two-sided 95% CIs and P-values. SAS Version
9.1 was used for all analyses.
Results
Baseline characteristics
Baseline demographics and clinical characteristics of patients
receiving either ivabradine (n = 1657) or placebo (n = 1700) in
the ≥ 77 b.p.m. subgroup are demonstrated in Table 1. The
median follow-up in SHIFT was 22.9 months (IQR 18–28
months). Patient characteristics were similar in both groups.
A majority of patients were in NYHA functional class II or III
and were optimally treated according to current GDMT
(90% having an angiotensin-converting-enzyme inhibitor or
angiotensin II receptor blockers and up to 60% having an al-
dosterone antagonist). Of the patients, 86% were treated
with a beta-blocker in both groups at the time of randomiza-
tion (carvedilol, bisoprolol, or metoprolol succinate), with up
to 25% and 55% at target beta-blocker dose or at least half
the target dose, respectively. Overall, the proportion of
patients implanted with pacemakers or implantable
cardioverter deﬁbrillators (ICDs) was low (<5% in both
groups). The mean dose of ivabradine was 6.74 ± 1.19 mg
bid. Median treatment duration was 20.96 months (±13.43)
in the ivabradine group and 20.91months (±13.66) in the pla-
cebo group.
Effects of ivabradine on patient-reported
outcomes in the ≥77 b.p.m. subgroup
Treatment with ivabradine was associated with a signiﬁcant
improvement in symptoms, as over one-quarter of patients
(28.0%, n = 460) in the ivabradine group had improvement
in functional status over the study period, vs. 22.7% (n =
382) in the placebo group (P = 0.0003). Global assessment
also signiﬁcantly improved from both patient (72.3%) and
Table 1 Baseline characteristics of patients with a heart rate ≥ 77 b.p.m. at rest
Baseline characteristics Ivabradine group (n = 1657) Placebo group (n = 1700) P
Age, mean (±SD) 59.5 (±11) 59.2 (±12) 0.7709
Female 23.9% (n = 396) 23.0% (n = 392) 0.5660
Caucasian 87.7% (n = 1454) 87.0% (n = 1479) 0.7745
Hypertension 65.1% (n = 1079) 63.5% (n = 1080) 0.3369
Diabetes 31.6% (n = 525) 32.6% (n = 555) 0.5503
History of atrial ﬁbrillation 7.4% (n = 124) 7.6% (n = 130) 0.8577
Ischaemic aetiology of HF 65.4% (n = 1084) 64.8% (n = 1103) 0.7440
BMI, kg/m2 mean (±SD) 28.1 (±5.4) 27.9 (±5.2) 0.4930
Heart rate, b.p.m. Median (IQR) 84 (77–130) 84 (77–142) 0.2338
Systolic blood pressure, mmHg mean (±SD) 121.7 (±17) 120.9 (±16) 0.2681
NYHA functional class 0.8947
I 0 0
II 45.7% (n = 758) 44.9% (n = 764)
III 52.0% (n = 862) 52.8% (n = 898)
IV 2.2% (n = 37) 2.2% (n = 38)
LVEF, %
mean (±SD)
28.5% (±5.2) 28.5% (±5.2) 0.7768
eGFR, mL/min/1.73 m2 mean (±SD) 75.8 (±23.9) 75.8 (±23.1) 0.8961
Treatments at study start or randomization
ACEi or ARBs 89.7% (n = 1487) 89.6% (n = 1524) 0.9291
Digitalis 23.9% (n = 397) 25.2% (n = 429) 0.3907
Aldosterone antagonist 63.1% (n = 1046) 61.1% (n = 1039) 0.2304
Beta-blockers, at study start or randomization 86.1% (n = 1428) 86.8% (n = 1476) 0.5852
Beta-blockers, target daily dose 26.0% (n = 366) 24.2% (n = 356) 0.3357
Beta-blockers, at least 50% of target dose daily 54.4% (n = 765) 54.4% (n = 792) 0.9900
Pacemaker or ICD or ICD + CRT 3.0% (n = 50) 4.8% (n = 83) 0.0056
ACEi, angiotensin-converting-enzyme inhibitor; ARB, angiotensin II receptor blocker; BMI, body mass index; CRT, cardiac
resynchronization therapy; eGFR, estimated glomerular ﬁltration rate; HF, heart failure; ICD, implantable cardioverter deﬁbrillator; IQR, in-
ter-quartile range; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; SD, standard deviation.
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physician (61.0%) perspectives with ivabradine when com-
pared with placebo (both P < 0.0001, Table 2). In patients
completing assessment at both baseline and last post-
baseline visit (n = 510), quality of life also improved with
ivabradine, as there was a signiﬁcant improvement in KCCQ
score over time (change in the KCCQ Clinical Summary Score
3.66 ± 18.51 vs. 1.24 ± 18.67 in the placebo group, P =
0.028; and change in the KCCQ Overall Summary Score
5.30 ± 18.54 vs. 2.19 ± 18.86 in the placebo group, P =
0.005; Table 3).
Effects of ivabradine on major outcomes in
patients with heart rate ≥ 77 b.p.m.
The effects of ivabradine on major outcomes in patients
with heart rate ≥ 77 b.p.m. are shown in Figures 1–3 and
Table 4. In addition to GDMT for chronic HFrEF, ivabradine
was associated with a 25% reduction in the primary end-
point, a composite of CV death, and hospitalization for
worsening HF (HR 0.75; 95% CI 0.67–0.85; P < 0.0001). Im-
portantly, the 25% decrease in the primary endpoint was
attributable to both a decrease in CV death (HR 0.81, P =
0.0137) and a decrease in HF hospitalization (HR 0.69,
P < 0.0001) (Figures 1–3). There was also a signiﬁcant re-
duction in CV hospitalization (decreased by 21%; HR 0.79;
95% CI 0.71–0.89; P < 0.0001), in CV death (decreased
by 19%; HR 0.81; 95% CI 0.69–0.96; P = 0.0137), in hospi-
talizations for HF (decreased by 31%; HR 0.69; 95% CI
0.59–0.80; P < 0.0001), in HF death (decreased by 39%;
HR 0.61; 95% CI 0.45–0.83; P = 0.0017), in all-cause hospi-
talization (decreased by 18%; HR 0.82; 95% CI 0.74–0.9; P =
0.0002), and in all-cause mortality alone (decreased by
19%; HR 0.81; 95% CI 0.69–0.94; P = 0.0074). The esti-
mated NNT (numbers needed to initiate treatment with
ivabradine to prevent pre-speciﬁed clinical outcomes within
1 year) in this group of patients was 17 for the primary
endpoint, 18 for CV hospitalization, 64 for CV death, 18
for hospitalization for worsening of HF, 94 for HF mortality,
17 for all-cause hospitalization, and 56 for all-cause
mortality.
Table 2 Change between baseline and last visit for New York Heart Association class and global assessment in patients with a heart rate ≥
77 b.p.m. at rest
Ivabradine group (N = 1657) Placebo group (N = 1700) P
NYHA functional class, % (n) Nobs = 1643 Nobs = 1680 0.0003
Improved 28.0% (n = 460) 22.7% (n = 382)
Stable or worsening 72.0% (n = 1183) 77.0% (n = 1298)
Change in global self-assessment, % (n) Nobs = 1497 Nobs = 1515 0.0006
Improved 72.3% (n = 1082) 66.6% (n = 1009)
Stable or worsening 27.7% (n = 415) 33.4% (n = 506)
Change in global assessment, physician perspective, % (n) Nobs = 1573 Nobs = 1596 <0.0001
Improved 61.0% (n = 960) 54. 5% (n = 869)
Stable or worsening 39.0% (n = 613) 45.5% (n = 727)
Nobs, number of observations; NYHA, New York Heart Association.
Table 3 Quality of life, subgroup of patients with a heart rate ≥ 77 b.p.m. at rest
KCCQ scores
Ivabradine
group
(N = 510)
Placebo group
(N = 512)
Treatment effect (change in QoL at 1 year)
Estimate (95% CI) P
CSS, at baseline mean (±SD) 66.58 (±20.74) 66.38 (±20.04) — —
CSS, changes at last post-baseline value mean (±SD) 3.66 (±18.51) 1.24 (±18.67) 2.37 (0.25–4.48) 0.028
OSS, at baseline mean (±SD) 63.27 (±20.67) 63.13 (±19.31) — —
OSS, changes at last post-baseline value mean (±SD) 5.30 (±18.54) 2.19 (±18.86) 3.00 (0.89–5.10) 0.005
CSS, clinical summary score; KCCQ, Kansas City Cardiomyopathy Questionnaire; OSS, overall summary score; QoL, quality of life.
Figure 1 Kaplan–Meier curves for the primary endpoint (composite of
cardiovascular mortality or hospitalization for worsening heart failure),
patients with a heart rate ≥ 77 b.p.m. at rest.
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Effects of ivabradine on left ventricular
remodelling in the ≥77 b.p.m. subgroup
In the SHIFT echocardiography sub-study, 95 patients in the
ivabradine group and 74 in placebo group had a baseline
heart rate ≥ 77 b.p.m. along with optimal image quality and
are included in the present sub-analysis. At baseline, mean
LVESVi was similar in both groups (68.7 ± 29.7 and 66.0 ±
28.0 mL/m2), as was LVEF (30.3 ± 9.1% and 29.4 ± 9.4% in
the ivabradine and placebo groups, respectively). At 8
months, there was a signiﬁcant reduction in LVESVi in pa-
tients treated with ivabradine (6.6 ± 17.8 vs. +2.3 ± 19.4
mL/m2, estimate standard error (SE) 8.3 (2.7), 95% CI
13.75 to 2.85; P = 0.003; Table 5), as well as in the left
ventricular end-diastolic volume index 7.5 ± 19.8 vs. +2.4
± 21.0 ml/m2, estimate (SE) 8.9 (3.1); 95% CI 15.04 to
2.76; P = 0.0047; Table 5]. There was also an improvement
in LVEF in the ivabradine group vs. placebo when reassessed
at 8 months (2.7 ± 8.2 in the ivabradine group vs. -0.1 ± 8.9 in
the placebo group, estimate (SE) 3.0 (1.3); 95% CI 0.52–5.64;
P = 0.0189; Table 5).
Discussion
This study demonstrates the following: (i) patients with HFrEF
and heart rate at rest > 77 b.p.m treated with ivabradine on
top of GDMT had a signiﬁcant improvement in symptoms,
quality of life, and global assessment; (ii) adding ivabradine
to GDMT signiﬁcantly reduced the occurrence of the primary
endpoint, a composite of CV death and hospitalization for
worsening HF, by 25%, attributable to both a decrease in
CV death and in HF hospitalization; and (iii) in addition, pa-
tients treated with ivabradine had a greater reduction in LV
dimensions over time. These results demonstrate the effects
of ivabradine on top of recommended medical therapy on
PRO, and reinforce its role in improving major outcomes in
patients with chronic HFrEF and baseline heart rate ≥ 77 b.
p.m.. Further analyses on other subgroups of patients could
consolidate these results in patients with lower heart rate
values at baseline.
Figure 2 Kaplan–Meier curves for cardiovascular mortality alone in pa-
tients with a heart rate ≥ 77 b.p.m. at rest.
Figure 3 Kaplan–Meier curves for hospitalization for worsening heart
failure alone in patients with a heart rate ≥ 77 b.p.m. at rest.
Table 4 Outcomes and treatment effect in patients with a heart rate ≥ 77 b.p.m. at rest
Outcomes, % (n) Treatment effect of ivabradine vs. placebo
Ivabradine (n = 1657) Placebo (n = 1700) NNT HR 95% CI P
CV mortality or hospitalization for
worsening HF
27.4% (n = 454) 34.1% (n = 581) 17 0.75 0.67–0.85 <0.0001
CV hospitalization 32.2% (n = 534) 38.0% (n = 647) 18 0.79 0.71–0.89 <0.0001
CV mortality 15.3% (n = 255) 18.3% (n = 312) 64 0.81 0.69–0.96 0.0137
Hospitalization for worsening HF 17.9% (n = 298) 24.5% (n = 418) 18 0.69 0.59–0.80 <0.0001
HF death 4.0% (n = 67) 6.2% (n = 107) 94 0.61 0.45–0.83 0.0017
All-cause hospitalization 40.2% (n = 667) 45.7% (n = 778) 17 0.82 0.74–0.91 0.0002
All-cause mortality 17.2% (n = 285) 20.5% (n = 350) 56 0.81 0.69–0.94 0.0074
CI, conﬁdence interval; CV, cardiovascular; HF, heart failure; HR, hazard ratio; NNT, number needed to be treated to prevent pre-speciﬁed
outcomes within 1 year.
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Ivabradine and patient-reported outcomes in
heart failure with reduced ejection fraction
Patients’ health status perceptions and global functioning are
increasingly considered as important outcome measures in
the setting of chronic disease.7 In patients with HF, PROs, that
is, symptoms, global function, and quality of life, proved to be
substantially impaired and have been associated with worse
prognosis.9 Moreover, PRO measures more accurately assess
some of the speciﬁc aspects of the disease process than do
conventional clinical tools.6–8 In this analysis, we demon-
strated that treatment with ivabradine was strongly associ-
ated with improved symptoms and self-reported global
assessment. We also demonstrate a signiﬁcant 5-point im-
provement in KCCQ overall summary score under ivabradine
treatment, which has been considered to be of signiﬁcant in-
terest in patients with HF.22 Improvement in symptoms and
functional status under ivabradine treatment has also been
demonstrated in elderly patients with HF, a group in which
co-morbidities and polypharmacy are frequent and may play
a role in PRO impairment.23 In addition to results from
SHIFT,15 the beneﬁcial effects of ivabradine on quality of life
measures have been demonstrated in various cohorts of
real-life patients,24 these effects being maintained in patients
followed up for at least 12 months.25 However, whether
these impacts on PRO are speciﬁcally related to ivabradine
or simply related to the global improvement in cardiac status
remains to be determined.
Ivabradine and clinical outcomes in patients with
heart failure with reduced ejection fraction and
heart rate > 77 b.p.m. at rest
Elevated heart rate at rest is associated with poor outcomes
in HFrEF,1,20,26–30 and some reports plead for a signiﬁcant sur-
vival beneﬁt related to heart rate lowering per se, indepen-
dently of the achievement of target doses of beta-blockers
in patients with HFrEF.31 In SHIFT, subgroup analyses showed
a signiﬁcant relationship between heart rate at baseline and
risk reduction under therapy, the beneﬁts from ivabradine
being independent from baseline medication.2,32 In the pres-
ent analysis, we demonstrate that in patients with a baseline
heart rate ≥ 77 b.p.m., the 25% decrease in the primary end-
point is attributable to a decrease both in CV death (HR 0.81,
P = 0.0137) and in HF hospitalization (HR 0.69, P < 0.0001),
whereas in the global SHIFT population, the effects of
ivabradine were mainly driven by a reduction in the numbers
of hospitalization for worsening HF (HR 0.64, P < 0.0001) and
no signiﬁcant effect on CV mortality (P = 0.128).20 Notably,
this reduction in CV deaths has already been demonstrated
in various subgroup analyses in patients with high heart rates
at baseline.1 These differences in the effectiveness of
ivabradine according to baseline heart rate may, at least inTa
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part, be explained by its mode of action, because If-channel
inhibition preferentially occurs when the If-channel is in its
opened state, that is, when heart rate is the highest.19,33,34
Ivabradine and left ventricular remodelling in
patients with heart failure with reduced ejection
fraction and heart rate > 77 b.p.m. at rest
In HFrEF, heart rate lowering with ivabradine has shown to be
associated with signiﬁcant LV structural changes that have
been associated with better survival.21,35 Furthermore, the
role of ivabradine in promoting LV reverse remodelling was
shown to be independent from baseline LVEF, LV volumes,
and background therapy21 and to be substantially more pro-
nounced in patients with higher heart rate at rest.2,21 In this
analysis, we demonstrate a signiﬁcant decrease in LV dimen-
sions in patients after 8months of treatment with ivabradine,
these results being consistent with those observed in the
overall SHIFT trial.21
Limitations
In this analysis, patients differed from those with HFrEF in the
global population, as they were younger, wre in sinus rhythm
(patients with known atrial ﬁbrillation were excluded consid-
ering the mechanism of action of the drug), a low proportion
of patients had ICDs, and recommended target doses of beta-
blockers often not being reached, limiting the ability to ex-
trapolate the results to all patients with HFrEF. Nonetheless,
the aforementioned analyses provide important insights with
regard to heart rate lowering in chronic HFrEF, particularly
with regard to PRO in the subgroup of patients with high
heart rates at baseline.
Conclusions
In patients with chronic HFrEF, sinus rhythm, and a baseline
heart rate ≥ 77 b.p.m. included in the SHIFT trial, treatment
with ivabradine on top of standard therapy for HFrEF im-
proved major clinical outcomes, including PROs.
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